PBR Nachrichten

 

Financial details of the transaction have not been disclosed. The partnership aims to deliver durable weight loss with improved tolerability, focusing on a target and modality of established The post InterAx and Alveus collaborate on small-molecule metabolic treatment appeared first on Pharmaceutical Business review....

The collaboration secures funding and sustained biologics manufacturing capacity in the US for Agenus, supporting clinical development, early access initiatives, and future commercial production. Under the agreement, Agenus The post Agenus and Zydus complete $141m BOT+BAL immunotherapy collaboration deal appeared first on Pharmaceutical Business review....

Menkes disease is a rare X-linked recessive disorder caused by mutations in the ATP7A gene, resulting in impaired copper absorption and transport. Zycubo is administered subcutaneously to restore The post Fortress Biotech receives FDA approval for Zycubo to treat Menkes disease appeared first on Pharmaceutical Business review....

The company aims to strengthen the pharmaceutical supply chain and accelerate the delivery of biologic and glucagon-like peptide-1 (GLP-1) drugs. BD will introduce Neopak Glass Prefillable Syringe manufacturing The post BD invests $110m to expand US prefillable syringe production appeared first on Pharmaceutical Business review....

The agreement will leverage SciNeuro's proprietary blood-brain barrier shuttle technology, aiming to deliver potential differentiation from current amyloid beta agents in development or on the market. Both companies The post SciNeuro and Novartis sign global licensing deal for Alzheimer's antibody appeared first on Pharmaceutical Business review....

The application sought approval for Ebvallo as monotherapy in adult and paediatric patients aged two years and above with Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have The post Atara receives FDA complete response letter for Ebvallo BLA application appeared first on Pharmaceutical Business review....

The facility forms a key component of the company's $23bn US investment programme, first outlined in April 2025, and aims to enhance the supply of RLT cancer treatments The post Novartis to build fourth US radioligand therapy facility in Florida appeared first on Pharmaceutical Business review....

Under the agreement, MediLink will receive upfront and near-term milestone payments totalling $570m. Additional development, regulatory, and commercial milestone payments are included in the deal, along with tiered The post MediLink and Roche announce exclusive licensing agreement for YL201c appeared first on Pharmaceutical Business review....

Through this partnership, Takeda aims to enhance patient care while exploring new opportunities for vedolizumab. Marketed as Entyvio, vedolizumab is approved for adults with moderately to severely active The post Takeda and Halozyme sign global agreement for Enhanze technology appeared first on Pharmaceutical Business review....

Agamree is a new drug that operates by attaching to the same receptor as glucocorticoids while altering its downstream activity. The agreement involves the development, manufacturing and commercialisation The post Santhera grants Agamree rights to Nxera for DMD appeared first on Pharmaceutical Business review....

The approval offers healthcare providers with an additional option alongside the existing 1g version. The new kit contains 100ml Water for Infusion (WFI) and includes the nextaro reconstitution The post Octapharma receives FDA approval for new Fibryga formulation in AFD appeared first on Pharmaceutical Business review....

The tender offer expired on 5 January 2026. The transaction involved purchasing all outstanding shares of Mersana at $25 per share in cash, along with one non-tradable contingent The post Day One concludes Mersana Therapeutics acquisition appeared first on Pharmaceutical Business review....

The approval applies to patients whose disease is metastatic or locally advanced, or where surgery may cause morbidity, and who have progressed on prior therapies or lack satisfactory The post Zai Lab's Augtyro receives NMPA approval for solid tumours in China appeared first on Pharmaceutical Business review....

The condition has an estimated prevalence of 25,000 patients in the US and an annual incidence of one to three new cases per 100,000 people. CK0804 is an The post Cellenkos gains FDA orphan drug status for CK0804 to treat myelofibrosis appeared first on Pharmaceutical Business review....

The first-in-class, subcutaneously administered hepcidin mimetic peptide, rusfertide is intended to regulate iron homeostasis and red blood cell production to help manage haematocrit levels in PV patients. The The post Takeda and Protagonist seek FDA approval for rusfertide to treat PV appeared first on Pharmaceutical Business review....

The approval provides a new treatment option for this rare condition, which is linked to extremely elevated triglyceride levels and an increased risk of acute, recurrent pancreatitis. Redemplo The post Arrowhead receives Health Canada authorisation for Redemplo to treat FCS appeared first on Pharmaceutical Business review....

The partnership combines Insilico's AI drug discovery platforms with Servier's expertise in cancer drug development, aiming to address challenging targets in the oncology field. Under the agreement, Insilico The post Insilico and Servier announce $888m oncology research agreement appeared first on Pharmaceutical Business review....

The company has assumed commercial rights for Byooviz from Biogen, and the product will now be available as a Samsung Bioepis brand across several European countries as part The post Samsung Bioepis initiates Byooviz commercialisation in Europe appeared first on Pharmaceutical Business review....

The approval is based on the Phase I/II GO29781 clinical study, with full approval contingent upon further confirmatory trials. Lunsumio VELO's SC injection requires around one minute, compared The post Genentech secures FDA approval for Lunsumio VELO SC for follicular lymphoma appeared first on Pharmaceutical Business review....

The move will give Samsung Biologics its first manufacturing site in the country as part of its long-term commitment to the market. The Rockville, Maryland facility is located The post Samsung Biologics to acquire Human Genome Sciences appeared first on Pharmaceutical Business review....